Search research articles
Contact Us
Filters
Showing results (11-20 of 13) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 13 results.
British Journal of Pharmacology
|
December 24, 2016
Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator
Simon E Ward, Paul Beswick, Novella Calcinaghi, et al.
Lancet (London, England)
|
May 23, 2015
Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial
Robert Pickard, Kathryn Starr, Graeme MacLennan, et al.
Health Technology Assessment (Winchester, England)
|
August 6, 2015
Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial)
Robert Pickard, Kathryn Starr, Graeme MacLennan, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 13) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 13 results.
British Journal of Pharmacology
|
December 24, 2016
Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator
Simon E Ward, Paul Beswick, Novella Calcinaghi, et al.
Lancet (London, England)
|
May 23, 2015
Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial
Robert Pickard, Kathryn Starr, Graeme MacLennan, et al.
Health Technology Assessment (Winchester, England)
|
August 6, 2015
Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial)
Robert Pickard, Kathryn Starr, Graeme MacLennan, et al.
Page
of 2